KalVista Plans Quick FDA Filing After Phase III Success In On-Demand HAE Therapy

 
• By Joseph Haas
Rare Diseases
KalVista hopes it has the latest advance in rare disease HAE • Source: Shutterstock

More from Clinical Trials

More from R&D